1.Craig, AT, Heywood, AE and Hall, J (2020) Risk of COVID-19 importation to the Pacific islands through global air travel. Epidemiology & Infection 148, e71.
2.Chen, TM et al. (2020) A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infectious Diseases of Poverty 9, 24.10.1186/s40249-020-00640-3
4.Guo, T et al. (2020) Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). JAMA Cardiology 2020, e201017.
5.Guan, WJ et al. (2020) Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. European Respiratory Journal 55, 2000547.10.1183/13993003.00547-2020
6.Chen, T et al. (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. British Medical Journal 368, m1091.
7.Zhou, F et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–62.
8.Wang, DW et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. The Journal of the American Medical Association 323, 1061–9.
9.Guan, WJ et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 382, 1708–20.
10.Rodriguez-Iturbe, B, Pons, H and Johnson, RJ (2017) Role of the immune system in hypertension. Physiological Reviews 97, 1127–64.10.1152/physrev.00031.2016
11.Moher, D et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6, e1000097.10.1371/journal.pmed.1000097
13.Chobanian, AV et al. (2003) The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. The Journal of the American Medical Association 289, 2560–72.10.1001/jama.289.19.2560
14.Stang, A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology 25, 603–5.
15.Greenland, S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiologic Reviews 9, 1–30.10.1093/oxfordjournals.epirev.a036298
17.Zhang, J et al. (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. doi: 10.1111/all.14238.
19.Chen, C et al. (2020) Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Chinese Journal Cardiology 48, E008.
20.Huang, C et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.10.1016/S0140-6736(20)30183-5
21.Yuan, ML et al. (2020) Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 15, e0230548.10.1371/journal.pone.0230548
23.Chen, L et al. (2020) Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhong hua Jie He He Hu Xi Za Zhi 43, 203–8.
24.Xiang, TX et al. (2020) Analysis of clinical characteristics of 49 patients with novel coronavirus pneumonia in Jiangxi province. Chinese Journal of Respiratory and Critical Care Medicine 19, 154–160.
26.Xu, M et al. (2020) Clinical analysis of 23 cases of 2019 novel coronavirus infection in Xinyang City, Henan Province. Chinese Critical Care Medicine 32, E010–E010.
27.Wan, Q et al. (2020) Analysis of clinical features of 153 patients with novel coronavirus pneumonia in Chongqing. Chinese Journal Clinical Infectious Disease 13, 16–20.
29.Fang, XW et al. (2020) Clinical characteristics and treatment strategies of 79 patients with COVID-19. Chinese Pharmacological Bulletin 36, 1–7.
30.Alqahtani, FY et al. (2018) Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiology & Infection 147, 1–5.
31.Mertz, D et al. (2013) Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. British Medical Journal 347, f5061.
32.Lan, J et al. (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–20.10.1038/s41586-020-2180-5
33.Chen, LJ et al. (2015) The ACE2/Apelin signaling, microRNAs, and hypertension. International Journal of Hypertension 2015, 896861.
34.Tipnis, SR et al. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. Journal of Biological Chemistry 275, 33238–43.
35.Jia, H (2016) Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 46, 239–48.
36.Kaparianos, A and Argyropoulou, E (2011) Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Current Medical Chemistry 18, 3506–15.10.2174/092986711796642562
37.Kuba, K et al. (2010) Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacology & Therapeutics 128, 119–28.
38.Hamming, I et al. (2007) The emerging role of ACE2 in physiology and disease. Journal of Pathology 212, 1–11.
39.Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China, 2020. China CDC Weekly 2, 113–22.